Hazards >> Carcinogenic substances to humans
Carcinogenic substances to humans
Most of the exposures that have been judged to cause cancer in humans have ocurred in the workplace. The designation of a substance as a human carcinogen requires judgement.
The International Agency for Research on Cancer has been reviewing the scientific literature on animal an human studies on potential carcinogens since 1971. Every year one or more working groups convene to review experimental and epidemiological studies in order to classify the carcinogenic potential of various substances in humans.
The IARC classification in use on the carcinogenity of a substance:
- Group 1: The agent is carcinogenic to humans
- Group 2A: The agent is probably carcinogenic to humans
- Group 2B: The agent is possibly carcinogenic to humans
- Group 3: The agent is not classifiable as to its carcinogenity to humans
- Group 4: The agent is probably not carcinogenic to humans
This list contains all agents evaluated as to their carcinogenity to humans, last updated March 2007.
Group 1: Carcinogenic to humans (101)
Agents and groups of agents
4-Aminobiphenyl [92-67-1] (Vol. 1, Suppl. 7; 1987)
Arsenic [7440-38-2] and arsenic compounds (Vol. 23, Suppl.
7; 1987)
(NB: This evaluation applies to the group of compounds
as a whole and not necessarily to all individual compounds
within the group)
Asbestos [1332-21-4] (Vol. 14, Suppl. 7; 1987)
Azathioprine [446-86-6] (Vol. 26, Suppl. 7; 1987)
Benzene [71-43-2] (Vol. 29, Suppl. 7; 1987)
Benzidine [92-87-5] (Vol. 29, Suppl. 7; 1987)
Benzo[a]pyrene [50-32-8] (Vol. 32, Suppl. 7, Vol.
92; in preparation)
(NB: Overall evaluation upgraded from 2B to 1 based on
mechanistic and other relevant data)
Beryllium [7440-41-7] and beryllium compounds (Vol. 58;
1993)
N,N-Bis(2-chloroethyl)-2-naphthylamine (Chlornaphazine) [494-03-1] (Vol. 4, Suppl. 7; 1987)
Bis(chloromethyl)ether [542-88-1] and chloromethyl methyl
ether [107-30-2] (technical-grade)
(Vol. 4, Suppl. 7; 1987)
1,4-Butanediol dimethanesulfonate (Busulphan; Myleran) [55-98-1] (Vol. 4, Suppl. 7; 1987)
Cadmium [7440-43-9] and cadmium compounds (Vol. 58; 1993)
Chlorambucil [305-03-3] (Vol. 26, Suppl. 7; 1987)
1-(2-Chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (Methyl-CCNU; Semustine) [13909-09-6] (Suppl. 7; 1987)
Chromium[VI] (Vol. 49; 1990)
Ciclosporin [79217-60-0] (Vol. 50; 1990)
Cyclophosphamide [50-18-0] [6055-19-2] (Vol. 26, Suppl. 7; 1987)
Diethylstilboestrol [56-53-1] (Vol. 21, Suppl. 7; 1987)
Epstein-Barr virus (Vol. 70; 1997)
Erionite [66733-21-9] (Vol. 42, Suppl. 7; 1987)
Estrogen-progestogen menopausal therapy (combined) (Vol. 72, Vol. 91; in preparation)
Estrogen-progestogen oral contraceptives (combined) (Vol.
72, Vol. 91; in preparation)
(NB: There is also convincing evidence in humans that
these agents confer a protective effect against cancer
in the endometrium and ovary)
Estrogens, nonsteroidal (Suppl. 7; 1987)
(NB: This evaluation applies to the group of compounds
as a whole and not necessarily to all individual compounds
within the group)
Estrogens, steroidal (Suppl. 7; 1987)
(NB: This evaluation applies to the group of compounds
as a whole and not necessarily to all individual compounds
within the group)
Estrogen therapy, postmenopausal (Vol. 72; 1999)
Ethanol [64-17-5] in alcoholic beverages (Vol. 96; 2007)
Ethylene oxide [75-21-8] (Vol. 60; 1994)
(NB: Overall evaluation upgraded from 2A to 1 with supporting
evidence from other relevant data)
Etoposide [33419-42-0] in combination with cisplatin
and bleomycin (Vol. 76; 2000)
Formaldehyde [50-00-0] (Vol. 88; 2006)
Gallium arsenide [1303-00-0] (Vol. 86; 2006)
[Gamma Radiation: see X- and Gamma (g)-Radiation]
Helicobacter pylori (infection with) (Vol. 61; 1994)
Hepatitis B virus (chronic infection with) (Vol. 59; 1994)
Hepatitis C virus (chronic infection with) (Vol. 59; 1994)
Human immunodeficiency virus type 1 (infection with) (Vol. 67; 1996)
Human papillomavirus types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59 and 66 (Vol. 64, Vol. 90; in preparation)
(NB: The HPV types that have been classified as carcinogenic
to humans can differ by an order of magnitude in risk
for cervical cancer)
Human T-cell lymphotropic virus type I (Vol. 67; 1996)
Melphalan [148-82-3] (Vol. 9, Suppl. 7; 1987)
8-Methoxypsoralen (Methoxsalen) [298-81-7] plus ultraviolet A radiation (Vol. 24, Suppl. 7; 1987)
MOPP and other combined chemotherapy including alkylating agents (Suppl. 7; 1987)
Mustard gas (Sulfur mustard) [505-60-2] (Vol. 9, Suppl. 7; 1987)
2-Naphthylamine [91-59-8] (Vol. 4, Suppl. 7; 1987)
Neutrons (Vol. 75; 2000)
(NB: Overall evaluation upgraded from 2B to 1 with supporting
evidence from other relevant data)
Nickel compounds (Vol. 49; 1990)
N'-Nitrosonornicotine (NNN) [16543-55-8] and 4-(N-Nitrosomethylamino)-1-(3-pyridyl)-1-butanone
(NNK) [64091-91-4] (Vol. 37, Suppl. 7, Vol. 89; in preparation)
(NB: Overall evaluation upgraded from 2B to 1 based on
mechanistic and other relevant data)
[Oestrogen: see Estrogen]
Opisthorchis viverrini (infection with) (Vol. 61; 1994)
[Oral contraceptives, combined estrogen-progestogen: see Estrogen-progestogen oral contraceptives (combined)]
Oral contraceptives, sequential (Suppl. 7; 1987)
Phosphorus-32, as phosphate (Vol. 78; 2001)
Plutonium-239 and its decay products (may contain plutonium-240 and other isotopes), as aerosols (Vol. 78; 2001)
Radioiodines, short-lived isotopes, including iodine-131, from atomic reactor accidents and nuclear weapons detonation (exposure during childhood) (Vol. 78; 2001)
Radionuclides, a-particle-emitting,
internally deposited (Vol. 78; 2001)
(NB: Specific radionuclides for which there is sufficient
evidence for carcinogenicity to humans are also listed
individually as Group 1 agents)
Radionuclides, b-particle-emitting,
internally deposited (Vol. 78; 2001)
(NB: Specific radionuclides for which there is sufficient
evidence for carcinogenicity to humans are also listed
individually as Group 1 agents)
Radium-224 and its decay products (Vol. 78; 2001)
Radium-226 and its decay products (Vol. 78; 2001)
Radium-228 and its decay products (Vol. 78; 2001)
Radon-222 [10043-92-2] and its decay products (Vol. 43, Vol. 78; 2001)
Schistosoma haematobium (infection with) (Vol. 61; 1994)
Silica [14808-60-7], crystalline (inhaled in the form of quartz or cristobalite from occupational sources) (Vol. 68; 1997)
Solar radiation (Vol. 55; 1992)
Talc containing asbestiform fibres (Vol. 42, Suppl. 7; 1987)
Tamoxifen [10540-29-1] (Vol. 66; 1996)
(NB: There is also conclusive evidence that tamoxifen
reduces the risk of contralateral breast cancer)
2,3,7,8-Tetrachlorodibenzo-para-dioxin [1746-01-6]
(Vol. 69; 1997)
(NB: Overall evaluation upgraded from 2A to 1 with supporting
evidence from other relevant data)
Thiotepa [52-24-4] (Vol. 50; 1990)
Thorium-232 and its decay products, administered intravenously as a colloidal dispersion of thorium-232 dioxide (Vol. 78; 2001)
Treosulfan [299-75-2] (Vol. 26, Suppl. 7; 1987)
Vinyl chloride [75-01-4] (Vol. 19, Suppl. 7; 1987)
X- and Gamma (g)-Radiation (Vol. 75; 2000)
Mixtures
Aflatoxins (naturally occurring mixtures of) [1402-68-2] (Vol. 56, Vol. 82; 2002)
Alcoholic beverages (Vol. 44, Vol. 96; 2007)
Areca nut (Vol. 85; 2004)
(NB: Overall evaluation based on human data, animal data,
and mechanistic and other relevant data)
Betel quid with tobacco (Vol. 85; 2004)
Betel quid without tobacco (Vol. 85; 2004)
Coal-tar pitches [65996-93-2] (Vol. 35, Suppl. 7; 1987)
Coal-tars [8007-45-2] (Vol. 35, Suppl. 7; 1987)
Herbal remedies containing plant species of the genus Aristolochia (Vol. 82; 2002)
Household combustion of coal, indoor emissions from (Vol. 95; in preparation)
Mineral oils, untreated and mildly treated (Vol. 33, Suppl. 7; 1987)
Phenacetin, analgesic mixtures containing (Suppl. 7;
1987)
Salted fish (Chinese-style) (Vol. 56; 1993)
Shale-oils [68308-34-9] (Vol. 35, Suppl. 7; 1987)
Soots (Vol. 35, Suppl. 7; 1987)
Tobacco, smokeless (Vol. 37, Suppl. 7, Vol. 89; in preparation)
Wood dust (Vol. 62; 1995)
Exposure circumstances
Aluminium production (Vol. 34, Suppl. 7; 1987)
Arsenic in drinking-water (Vol. 84; 2004)
Auramine, manufacture of (Suppl. 7; 1987)
Boot and shoe manufacture and repair (Vol. 25, Suppl. 7; 1987)
Chimney sweeping (Vol. 92; in preparation)
Coal gasification (Vol. 34, Suppl. 7, Vol. 92; in preparation)
Coal-tar distillation (Vol. 92; in preparation)
Coke production (Vol. 34, Suppl. 7, Vol. 92; in preparation)
Furniture and cabinet making (Vol. 25, Suppl. 7; 1987)
Haematite mining (underground) with exposure to radon
(Vol. 1, Suppl. 7; 1987)
Involuntary smoking (exposure to secondhand or 'environmental'
tobacco smoke) (Vol. 83; 2004)
Iron and steel founding (Vol. 34, Suppl. 7; 1987)
Isopropyl alcohol manufacture (strong-acid process) (Suppl. 7; 1987)
Magenta, manufacture of (Vol. 57; 1993)
Painter (occupational exposure as a) (Vol. 47; 1989)
Paving and roofing with coal-tar pitch (Vol. 92; in preparation)
Rubber industry (Vol. 28, Suppl. 7; 1987)
Strong-inorganic-acid mists containing sulfuric acid (occupational exposure to) (Vol. 54; 1992)
Tobacco smoking and tobacco smoke (Vol. 83; 2004)
Group 2A: Probably carcinogenic to humans (69)
Agents and groups of agents
Acrylamide [79-06-1] (Vol. 60; 1994)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Adriamycin [23214-92-8] (Vol. 10, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Androgenic (anabolic) steroids (Suppl. 7; 1987)
Aristolochic acids (naturally occurring mixtures of) (Vol. 82; 2002)
Azacitidine [320-67-2] (Vol. 50; 1990)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Benzidine-based dyes (Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Bischloroethyl nitrosourea (BCNU) [154-93-8] (Vol. 26, Suppl.7; 1987)
1,3-Butadiene [106-99-0] (Vol. 71; 1999)
Captafol [2425-06-1] (Vol. 53; 1991)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Chloramphenicol [56-75-7] (Vol. 50; 1990)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
a-Chlorinated toluenes (benzal chloride [98-87-3], benzotrichloride [98-07-7], benzyl chloride [100-44-7]) and benzoyl chloride [98-88-4] (combined exposures) (Vol. 29, Suppl. 7, Vol. 71; 1999)
1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) [13010-47-4](Vol.
26, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
4-Chloro-ortho-toluidine [95-69-2] (Vol. 77; 2000)
Chlorozotocin [54749-90-5] (Vol. 50; 1990)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Cisplatin [15663-27-1] (Vol. 26, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Clonorchis sinensis (infection with) (Vol. 61;
1994)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Cyclopenta[cd]pyrene [27208-37-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dibenz[a,h]anthracene [53-70-3] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dibenzo[a,l]pyrene [191-30-0] (Vol. 32,
Suppl. 7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Diethyl sulfate [64-67-5] (Vol. 54, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dimethylcarbamoyl chloride [79-44-7] (Vol. 12, Suppl.
7, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
1,2-Dimethylhydrazine [540-73-8] (Vol. 4, Suppl. 7, Vol.
71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Dimethyl sulfate [77-78-1] (Vol. 4, Suppl. 7, Vol. 71;
1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Epichlorohydrin [106-89-8] (Vol. 11, Suppl. 7, Vol. 71;
1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ethyl carbamate (urethane) [51-79-6] (Vol. 7, Suppl.
7, Vol. 96; 2007)
(NB: Overall evaluation upgraded from 2B to 2A based on
mechanistic data and other relevant data)
Ethylene dibromide [106-93-4] (Vol. 15, Suppl. 7, Vol.
71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Ethyl-N-nitrosourea [759-73-9] (Vol.
17, Suppl.7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Etoposide [33419-42-0] (Vol. 76; 2000)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Glycidol [556-52-5] (Vol. 77; 2000)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Indium phosphide [22398-80-7] (Vol. 86; 2006)
(NB: Overall evaluation upgraded from 2B to 2A)
IQ (2-Amino-3-methylimidazo[4,5-f]quinoline) [76180-96-6]
(Vol. 56; 1993)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Kaposi's sarcoma herpesvirus/human herpesvirus 8 (Vol. 70; 1997)
Lead compounds, inorganic (Vol. 87; 2006)
5-Methoxypsoralen [484-20-8] (Vol. 40, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
4,4´-Methylene bis(2-chloroaniline) (MOCA) [101-14-4]
(Vol.57; 1993)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Methyl methanesulfonate [66-27-3] (Vol. 7, Suppl. 7,
Vol. 71; 1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Methyl-N´-nitro-N-nitrosoguanidine(MNNG)
[70-25-7] (Vol. 4, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Methyl-N-nitrosourea [684-93-5] (Vol.
17, Suppl.7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Nitrate or nitrite (ingested) under conditions that result in endogenous nitrosation (Vol. 94; in preparation)
Nitrogen mustard [51-75-2] (Vol. 9, Suppl. 7; 1987)
N-Nitrosodiethylamine [55-18-5] (Vol. 17, Suppl.
7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
N-Nitrosodimethylamine [62-75-9] (Vol. 17, Suppl.
7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Phenacetin [62-44-2] (Vol. 24, Suppl. 7; 1987)
Procarbazine hydrochloride [366-70-1] (Vol. 26, Suppl.
7; 1987)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Styrene-7,8-oxide [96-09-3] (Vol. 60; 1994)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Teniposide [29767-20-2] (Vol. 76; 2000)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Tetrachloroethylene [127-18-4] (Vol. 63; 1995)
ortho-Toluidine [95-53-4] (Vol. 77; 2000)
Trichloroethylene [79-01-6] (Vol. 63; 1995)
1,2,3-Trichloropropane [96-18-4] (Vol. 63; 1995)
Tris(2,3-dibromopropyl) phosphate [126-72-7] (Vol. 20,
Suppl. 7, Vol. 71;1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ultraviolet radiation A (Vol. 55; 1992)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ultraviolet radiation B (Vol. 55; 1992)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Ultraviolet radiation C (Vol. 55; 1992)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
[Urethane: see Ethyl carbamate]
Vinyl bromide [593-60-2] (Vol. 39, Suppl. 7, Vol. 71;
1999)
(NB: Overall evaluation upgraded from 2B to 2A with supporting
evidence from other relevant data)
Vinyl fluoride [75-02-5] (Vol. 63; 1995)
Mixtures
Creosotes [8001-58-9] (Vol. 35, Suppl. 7, Vol. 92; in preparation)
Diesel engine exhaust (Vol. 46; 1989)
High-temperature frying, emissions from (Vol. 95; in preparation)
Hot mate (Vol. 51; 1991)
Household combustion of biomass fuel (primarily wood), indoor emissions from (Vol. 95; in preparation)
Non-arsenical insecticides (occupational exposures in spraying and application of) (Vol. 53; 1991)
Polychlorinated biphenyls [1336-36-3] (Vol. 18, Suppl. 7; 1987)
Exposure circumstances
Art glass, glass containers and pressed ware (manufacture of) (Vol. 58; 1993)
Carbon electrode manufacture (Vol. 92; in preparation)
Cobalt metal with tungsten carbide (Vol. 86; 2006)
Hairdresser or barber (occupational exposure as a) (Vol. 57; 1993)
Petroleum refining (occupational exposures in) (Vol. 45; 1989)
Sunlamps and sunbeds (use of) (Vol. 55; 1992)
Group 2B: Possibly carcinogenic to humans (245)
Agents and groups of agents
A-a-C (2-Amino-9H-pyrido[2,3-b]indole) [26148-68-5] (Vol. 40, Suppl. 7; 1987)
Acetaldehyde [75-07-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Acetamide [60-35-5] (Vol. 7, Suppl. 7, Vol. 71; 1999)
Acrylonitrile [107-13-1] (Vol. 71; 1999)
AF-2 [2-(2-Furyl)-3-(5-nitro-2-furyl)acrylamide] [3688-53-7] (Vol.31, Suppl. 7; 1987)
Aflatoxin M1 [6795-23-9] (Vol. 56; 1993)
para-Aminoazobenzene [60-09-3] (Vol. 8, Suppl. 7; 1987)
ortho-Aminoazotoluene [97-56-3] (Vol. 8, Suppl. 7; 1987)
2-Amino-5-(5-nitro-2-furyl)-1,3,4-thiadiazole [712-68-5] (Vol. 7, Suppl. 7; 1987)
Amsacrine [51264-14-3] (Vol. 76; 2000)
ortho-Anisidine [90-04-0] (Vol. 73; 1999)
Antimony trioxide [1309-64-4] (Vol. 47; 1989)
Aramite® [140-57-8] (Vol. 5, Suppl. 7; 1987)
Auramine [492-80-8] (technical-grade) (Vol. 1, Suppl. 7; 1987)
Azaserine [115-02-6] (Vol. 10, Suppl. 7; 1987)
Aziridine [151-56-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Benz[j]aceanthrylene [202-33-5] (Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
mechanistic and other relevant data)
Benz[a]anthracene [56-55-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[b]fluoranthene [205-99-2] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[j]fluoranthene [205-82-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[k]fluoranthene [207-08-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzofuran [271-89-6] (Vol. 63; 1995)
Benzo[c]phenanthrene [195-19-7] (Vol. 32, Suppl.
7, Vol. 92; in preparation)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Benzyl violet 4B [1694-09-3] (Vol. 16, Suppl. 7; 1987)
2,2-Bis(bromomethyl)propane-1,3-diol [3296-90-0] (Vol. 77; 2000)
Bleomycins [11056-06-7] (Vol. 26, Suppl. 7; 1987)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Bracken fern (Vol. 40, Suppl. 7; 1987)
Bromodichloromethane [75-27-4] (Vol. 52, Vol. 71; 1999)
Butylated hydroxyanisole (BHA) [25013-16-5] (Vol. 40, Suppl. 7;1987)
b-Butyrolactone [3068-88-0] (Vol. 11, Suppl. 7, Vol. 71; 1999)
Caffeic acid [331-39-5] (Vol. 56; 1993)
Carbon black [1333-86-4] (Vol. 65, Vol. 93; in preparation)
Carbon tetrachloride [56-23-5] (Vol. 20, Suppl. 7, Vol. 71; 1999)
Catechol [120-80-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)
Chlordane [57-74-9] (Vol. 79; 2001)
Chlordecone (Kepone) [143-50-0] (Vol. 20, Suppl. 7; 1987)
Chlorendic acid [115-28-6] (Vol. 48; 1990)
para-Chloroaniline [106-47-8] (Vol. 57; 1993)
3-Chloro-4-(dichloromethyl)-5-hydroxy-2(5H)-furanone [77439-76-0] (Vol. 84; 2004)
Chloroform [67-66-3] (Vol. 73; 1999)
1-Chloro-2-methylpropene [513-37-1] (Vol. 63; 1995)
Chlorophenoxy herbicides (Vol. 41, Suppl. 7; 1987)
4-Chloro-ortho-phenylenediamine [95-83-0] (Vol. 27, Suppl.7; 1987)
Chloroprene [126-99-8] (Vol. 71; 1999)
Chlorothalonil [1897-45-6] (Vol. 73; 1999)
Chrysene [218-01-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
CI Acid Red 114 [6459-94-5] (Vol. 57; 1993)
CI Basic Red 9 [569-61-9] (Vol. 57; 1993)
CI Direct Blue 15 [2429-74-5] (Vol. 57; 1993)
Citrus Red No. 2 [6358-53-8] (Vol. 8, Suppl. 7; 1987)
Cobalt [7440-48-4] and cobalt compounds (Vol. 52; 1991)
(NB: Evaluated as a group)
Cobalt sulfate [10026-24-1] and other soluble cobalt(II) salts (Vol. 86; 2006)
para-Cresidine [120-71-8] (Vol. 27, Suppl. 7; 1987)
Cycasin [14901-08-7] (Vol. 10, Suppl. 7; 1987)
Dacarbazine [4342-03-4] (Vol. 26, Suppl. 7; 1987)
Dantron (Chrysazin; 1,8-Dihydroxyanthraquinone) [117-10-2] (Vol. 50; 1990)
Daunomycin [20830-81-3] (Vol. 10, Suppl. 7; 1987)
DDT [p,p'-DDT, 50-29-3] (Vol. 53; 1991)
N,N'-Diacetylbenzidine [613-35-4] (Vol. 16, Suppl.7; 1987)
2,4-Diaminoanisole [615-05-4] (Vol. 79; 2001)
4,4'-Diaminodiphenyl ether [101-80-4] (Vol. 29, Suppl. 7; 1987)
2,4-Diaminotoluene [95-80-7] (Vol. 16, Suppl. 7; 1987)
Dibenz[a,h]acridine [226-36-8] (Vol. 32, Suppl. 7; 1987)
Dibenz[a,j]acridine [224-42-0] (Vol. 32, Suppl. 7; 1987)
7H-Dibenzo[c,g]carbazole [194-59-2] (Vol. 32, Suppl.7; 1987)
Dibenzo[a,h]pyrene [189-64-0] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Dibenzo[a,i]pyrene [189-55-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
1,2-Dibromo-3-chloropropane [96-12-8] (Vol. 20, Suppl. 7, Vol. 71; 1999)
2,3-Dibromopropan-1-ol [96-13-9] (Vol. 77; 2000)
Dichloroacetic acid [79-43-6] (Vol. 84; 2004)
para-Dichlorobenzene [106-46-7] (Vol. 73; 1999)
3,3'-Dichlorobenzidine [91-94-1] (Vol. 29, Suppl. 7; 1987)
3,3'-Dichloro-4,4'-diaminodiphenyl ether [28434-86-8] (Vol. 16,Suppl. 7; 1987)
1,2-Dichloroethane [107-06-2] (Vol. 20, Suppl. 7, Vol. 71; 1999)
Dichloromethane (methylene chloride) [75-09-2] (Vol. 71; 1999)
1,3-Dichloropropene [542-75-6] (technical-grade) (Vol. 41, Suppl.7, Vol. 71; 1999)
Dichlorvos [62-73-7] (Vol. 53; 1991)
1,2-Diethylhydrazine [1615-80-1] (Vol. 4, Suppl. 7, Vol. 71; 1999)
Diglycidyl resorcinol ether [101-90-6] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Dihydrosafrole [94-58-6] (Vol. 10, Suppl. 7; 1987)
Diisopropyl sulfate [2973-10-6] (Vol. 54, Vol. 71; 1999)
3,3'-Dimethoxybenzidine (ortho-Dianisidine) [119-90-4] (Vol. 4, Suppl. 7; 1987)
para-Dimethylaminoazobenzene [60-11-7] (Vol. 8, Suppl. 7; 1987)
trans-2-[(Dimethylamino)methylimino]-5-[2-(5-nitro-2-furyl)-vinyl]-1,3,4-oxadiazole
[25962-77-0]
(Vol. 7, Suppl. 7; 1987)
2,6-Dimethylaniline (2,6-Xylidine) [87-62-7] (Vol. 57; 1993)
3,3'-Dimethylbenzidine (ortho-Tolidine) [119-93-7] (Vol.1, Suppl. 7; 1987)
1,1-Dimethylhydrazine [57-14-7] (Vol. 4, Suppl. 7, Vol. 71; 1999)
3,7-Dinitrofluoranthene [105735-71-5] (Vol. 65; 1996)
3,9-Dinitrofluoranthene [22506-53-2] (Vol. 65; 1996)
1,6-Dinitropyrene [42397-64-8] (Vol. 46; 1989)
1,8-Dinitropyrene [42397-65-9] (Vol. 46; 1989)
2,4-Dinitrotoluene [121-14-2] (Vol. 65; 1996)
2,6-Dinitrotoluene [606-20-2] (Vol. 65; 1996)
1,4-Dioxane [123-91-1] (Vol. 11, Suppl. 7, Vol. 71; 1999)
Disperse Blue 1 [2475-45-8] (Vol. 48; 1990)
1,2-Epoxybutane [106-88-7] (Vol. 47, Vol. 71; 1999)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Ethyl acrylate [140-88-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)
Ethylbenzene [100-41-4] (Vol. 77; 2000)
Ethyl methanesulfonate [62-50-0] (Vol. 7, Suppl. 7; 1987)
[Foreign bodies: see Surgical implants and other foreign bodies]
2-(2-Formylhydrazino)-4-(5-nitro-2-furyl)thiazole [3570-75-0] (Vol. 7, Suppl. 7; 1987)
Fumonisin B1 [116355-83-0] (Vol. 82; 2002)
Furan [110-00-9] (Vol. 63; 1995)
Glu-P-1 (2-Amino-6-methyldipyrido[1,2-a:3',2'-d]imidazole) [67730-11-4] (Vol. 40, Suppl. 7; 1987)
Glu-P-2 (2-Aminodipyrido[1,2-a:3',2'-d]imidazole)[67730-10-3] (Vol. 40, Suppl. 7; 1987)
Glycidaldehyde [765-34-4] (Vol. 11, Suppl. 7, Vol. 71; 1999)
Griseofulvin [126-07-8] (Vol. 79; 2001)
HC Blue No. 1 [2784-94-3] (Vol. 57; 1993)
Heptachlor [76-44-8] (Vol. 79; 2001)
Hexachlorobenzene [118-74-1] (Vol. 79; 2001)
Hexachloroethane [67-72-1] (Vol. 73; 1999)
Hexachlorocyclohexanes (Vol. 20, Suppl. 7; 1987)
Hexamethylphosphoramide [680-31-9] (Vol. 15, Suppl. 7, Vol. 71; 1999)
Human immunodeficiency virus type 2 (infection with) (Vol. 67; 1996)
Human papillomavirus types 6 and 11 (Vol. 90; in preparation)
Human papillomavirus genus beta (some types) (Vol. 90; in preparation)
Hydrazine [302-01-2] (Vol. 4, Suppl. 7, Vol. 71; 1999)
1-Hydroxyanthraquinone [129-43-1] (Vol. 82; 2002)
Indeno[1,2,3-cd]pyrene [193-39-5] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Iron-dextran complex [9004-66-4] (Vol. 2, Suppl. 7; 1987)
Isoprene [78-79-5] (Vol. 60, Vol. 71; 1999)
Lasiocarpine [303-34-4] (Vol. 10, Suppl. 7; 1987)
Lead [7439-92-1] (Vol. 23, Suppl. 7; 1987)
Magenta [632-99-5] (containing CI Basic Red 9) (Vol. 57; 1993)
Magnetic fields (extremely low-frequency) (Vol. 80; 2002)
MeA-a-C (2-Amino-3-methyl-9H-pyrido[2,3-b]indole) [68006-83-7] (Vol. 40, Suppl. 7; 1987)
Medroxyprogesterone acetate [71-58-9] (Vol. 21, Suppl. 7; 1987)
MeIQ (2-Amino-3,4-dimethylimidazo[4,5-f]quinoline) [77094-11-2] (Vol. 56; 1993)
MeIQx (2-Amino-3,8-dimethylimidazo[4,5-f]quinoxaline) [77500-04-0] (Vol. 56; 1993)
Merphalan [531-76-0] (Vol. 9, Suppl. 7; 1987)
2-Methylaziridine (Propyleneimine) [75-55-8] (Vol. 9, Suppl. 7, Vol. 71; 1999)
Methylazoxymethanol acetate [592-62-1] (Vol. 10, Suppl. 7; 1987)
5-Methylchrysene [3697-24-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
4,4'-Methylene bis(2-methylaniline) [838-88-0] (Vol. 4, Suppl.7; 1987)
4,4'-Methylenedianiline [101-77-9] (Vol. 39, Suppl. 7; 1987)
Methylmercury compounds (Vol. 58; 1993)
(NB: Evaluated as a group)
2-Methyl-1-nitroanthraquinone [129-15-7] (uncertain purity) (Vol.27, Suppl. 7; 1987)
N-Methyl-N-nitrosourethane [615-53-2] (Vol. 4, Suppl.7; 1987)
Methylthiouracil [56-04-2] (Vol. 79; 2001)
Metronidazole [443-48-1] (Vol. 13, Suppl. 7; 1987)
Microcystin-LR [101043-37-2] (Vol. 94; in preparation)
(NB: Overall evaluation upgraded from 3 to 2B based on
mechanistic and other relevant data)
Mirex [2385-85-5] (Vol. 20, Suppl. 7; 1987)
Mitomycin C [50-07-7] (Vol. 10, Suppl. 7; 1987)
Mitoxantrone [65271-80-9] (Vol. 76; 2000)
Monocrotaline [315-22-0] (Vol. 10, Suppl. 7; 1987)
5-(Morpholinomethyl)-3-[(5-nitrofurfurylidene)amino]-2-oxazolidinone [3795-88-8] (Vol. 7, Suppl. 7; 1987)
Nafenopin [3771-19-5] (Vol. 24, Suppl. 7; 1987)
Naphthalene [91-20-3] (Vol. 82; 2002)
Nickel, metallic [7440-02-0] and alloys (Vol. 49; 1990)
Niridazole [61-57-4] (Vol. 13, Suppl. 7; 1987)
Nitrilotriacetic acid [139-13-9] and its salts (Vol.
73; 1999)
(NB: Evaluated as a group)
5-Nitroacenaphthene [602-87-9] (Vol. 16, Suppl. 7; 1987)
2-Nitroanisole [91-23-6] (Vol. 65; 1996)
Nitrobenzene [98-95-3] (Vol. 65; 1996)
6-Nitrochrysene [7496-02-8] (Vol. 46; 1989)
Nitrofen [1836-75-5] (technical-grade) (Vol. 30, Suppl. 7; 1987)
2-Nitrofluorene [607-57-8] (Vol. 46; 1989)
1-[(5-Nitrofurfurylidene)amino]-2-imidazolidinone [555-84-0] (Vol.7, Suppl. 7; 1987)
N-[4-(5-Nitro-2-furyl)-2-thiazolyl]acetamide [531-82-8] (Vol. 7, Suppl. 7; 1987)
Nitrogen mustard N-oxide [126-85-2] (Vol. 9, Suppl. 7;1987)
Nitromethane [75-52-5] (Vol. 77; 2000)
2-Nitropropane [79-46-9] (Vol. 29, Suppl. 7, Vol. 71; 1999)
1-Nitropyrene [5522-43-0] (Vol. 46; 1989)
4-Nitropyrene [57835-92-4] (Vol. 46; 1989)
N-Nitrosodi-n-butylamine [924-16-3] (Vol. 17, Suppl.7; 1987)
N-Nitrosodiethanolamine [1116-54-7] (Vol. 17, Suppl. 7, Vol. 77; 2000)
N-Nitrosodi-n-propylamine [621-64-7] (Vol. 17, Suppl.7; 1987)
3-(N-Nitrosomethylamino)propionitrile [60153-49-3] (Vol. 85; 2004)
N-Nitrosomethylethylamine [10595-95-6] (Vol. 17, Suppl. 7; 1987)
N-Nitrosomethylvinylamine [4549-40-0] (Vol. 17, Suppl. 7; 1987)
N-Nitrosomorpholine [59-89-2] (Vol. 17, Suppl. 7; 1987)
N-Nitrosopiperidine [100-75-4] (Vol. 17, Suppl. 7; 1987)
N-Nitrosopyrrolidine [930-55-2] (Vol. 17, Suppl. 7; 1987)
N-Nitrososarcosine [13256-22-9] (Vol. 17, Suppl. 7; 1987)
Ochratoxin A [303-47-9] (Vol. 56; 1993)
Oil Orange SS [2646-17-5] (Vol. 8, Suppl. 7; 1987)
Oxazepam [604-75-1] (Vol. 66; 1996)
Palygorskite (attapulgite) [12174-11-7] (long fibres, > 5 micrometres) (Vol. 68; 1997)
Panfuran S [794-93-4] (containing dihydroxymethylfuratrizine)
(Vol. 24, Suppl. 7; 1987)
Phenazopyridine hydrochloride [136-40-3] (Vol. 24, Suppl. 7; 1987)
Phenobarbital [50-06-6] (Vol. 79; 2001)
Phenolphthalein [77-09-8] (Vol. 76; 2000)
Phenoxybenzamine hydrochloride [63-92-3] (Vol. 24, Suppl. 7; 1987)
Phenyl glycidyl ether [122-60-1] (Vol. 47, Vol. 71; 1999)
Phenytoin [57-41-0] (Vol. 66; 1996)
PhIP (2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine) [105650-23-5] (Vol. 56; 1993)
Polychlorophenols and their sodium salts (mixed exposures) (Vol. 41, Suppl. 7, Vol. 53, Vol. 71; 1999)
Ponceau MX [3761-53-3] (Vol. 8, Suppl. 7; 1987)
Ponceau 3R [3564-09-8] (Vol. 8, Suppl. 7; 1987)
Potassium bromate [7758-01-2] (Vol. 73; 1999)
Progestins (Suppl. 7; 1987)
Progestogen-only contraceptives (Vol. 72; 1999)
1,3-Propane sultone [1120-71-4] (Vol. 4, Suppl. 7, Vol. 71; 1999)
b-Propiolactone [57-57-8] (Vol. 4, Suppl. 7, Vol. 71; 1999)
Propylene oxide [75-56-9] (Vol. 60; 1994)
Propylthiouracil [51-52-5] (Vol. 79; 2001)
Refractory ceramic fibres (Vol. 43, Vol. 81; 2002)
Riddelliine [23246-96-0] (Vol. 10, Suppl. 7, Vol. 82; 2002)
Safrole [94-59-7] (Vol. 10, Suppl. 7; 1987)
Schistosoma japonicum (infection with) (Vol. 61; 1994)
Sodium ortho-phenylphenate [132-27-4] (Vol. 73; 1999)
Special-purpose fibres such as E-glass and '475' glass fibres (Vol. 81; 2002)
Sterigmatocystin [10048-13-2] (Vol. 10, Suppl. 7; 1987)
Streptozotocin [18883-66-4] (Vol. 17, Suppl. 7; 1987)
Styrene [100-42-5] (Vol. 60, 82; 2002)
Sulfallate [95-06-7] (Vol. 30, Suppl. 7; 1987)
Surgical implants and other foreign bodies (Vol. 74;
1999):
- Polymeric implants prepared as thin smooth film (with
the exception of poly(glycolic acid))
- Metallic implants prepared as thin smooth films
- Implanted foreign bodies of metallic cobalt, metallic
nickel and an alloy powder containing 66-67% nickel, 13-16%
chromium and 7% iron
Tetrafluoroethylene [116-14-3] (Vol. 19, Suppl. 7, Vol. 71; 1999)
Tetranitromethane [509-14-8] (Vol. 65; 1996)
Thioacetamide [62-55-5] (Vol. 7, Suppl. 7; 1987)
4,4'-Thiodianiline [139-65-1] (Vol. 27, Suppl. 7; 1987)
Titanium dioxide [13463-67-7] (Vol. 47, Vol. 93; in preparation)
Thiouracil [141-90-2] (Vol. 79; 2001)
Toluene diisocyanates [26471-62-5] (Vol. 39, Suppl. 7, Vol. 71; 1999)
Trichlormethine (Trimustine hydrochloride) [817-09-4] (Vol. 50; 1990)
Trp-P-1 (3-Amino-1,4-dimethyl-5H-pyrido[4,3-b]indole)[62450-06-0] (Vol. 31, Suppl. 7; 1987)
Trp-P-2 (3-Amino-1-methyl-5H-pyrido[4,3-b]indole)[62450-07-1] (Vol. 31, Suppl. 7; 1987)
Trypan blue [72-57-1] (Vol. 8, Suppl. 7; 1987)
Uracil mustard [66-75-1] (Vol. 9, Suppl. 7; 1987)
Vanadium pentoxide [1314-62-1] (Vol. 86; in preparation)
Vinyl acetate [108-05-4] (Vol. 63; 1995)
4-Vinylcyclohexene [100-40-3] (Vol. 60; 1994)
4-Vinylcyclohexene diepoxide [106-87-6] (Vol. 60; 1994)
Zalcitabine [7481-89-2] (Vol. 76; 2000)
Zidovudine (AZT) [30516-87-1] (Vol. 76; 2000)
Mixtures
Bitumens [8052-42-4], extracts of steam-refined and air-refined (Vol. 35, Suppl. 7; 1987)
Carrageenan [9000-07-1], degraded (Vol. 31, Suppl. 7; 1987)
Chlorinated paraffins of average carbon chain length C12 and average degree of chlorination approximately 60% (Vol. 48; 1990)
Coffee (urinary bladder) (Vol. 51; 1991)
(NB: There is some evidence of an inverse relationship
between coffee drinking and cancer of the large bowel;
coffee drinking could not be classified as to its carcinogenicity
to other organs)
Diesel fuel, marine (Vol. 45; 1989)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Engine exhaust, gasoline (Vol. 46; 1989)
Fuel oils, residual (heavy) (Vol. 45; 1989)
Gasoline (Vol. 45; 1989)
(NB: Overall evaluation upgraded from 3 to 2B with supporting
evidence from other relevant data)
Pickled vegetables (traditional in Asia) (Vol. 56; 1993)
Polybrominated biphenyls [Firemaster BP-6, 59536-65-1] (Vol. 41, Suppl. 7; 1987)
Toxaphene (Polychlorinated camphenes) [8001-35-2] (Vol. 79; 2001)
Toxins derived from Fusarium moniliforme: fumonisin B1 and B2 and fusarin C (Vol. 56; 1993)
Welding fumes (Vol. 49; 1990)
Exposure circumstances
Carpentry and joinery (Vol. 25, Suppl. 7; 1987)
Cobalt metal without tungsten carbide (Vol. 86; 2006)
Dry cleaning (occupational exposures in) (Vol. 63; 1995)
Printing processes (occupational exposures in) (Vol. 65; 1996)
Talc-based body powder (perineal use of) (Vol. 93; in preparation)
Textile manufacturing industry (work in) (Vol. 48; 1990)
Group 3: Not classifiable as to its carcinogenicity to humans (516)
Agents and groups of agents
Acenaphthene [83-32-9] (Vol. 92; in preparation)
Acepyrene (3,4-dihydrocyclopenta[cd]pyrene) [25732-74-5] (Vol. 92; in preparation)
Aciclovir [59277-89-3] (Vol. 76; 2000)
Acridine orange [494-38-2] (Vol. 16, Suppl. 7; 1987)
Acriflavinium chloride [8018-07-3] (Vol. 13, Suppl. 7; 1987)
Acrolein [107-02-8] (Vol. 63; 1995)
Acrylic acid [79-10-7] (Vol. 19, Suppl. 7, Vol. 71; 1999)
Acrylic fibres (Vol. 19, Suppl. 7; 1987)
Acrylonitrile-butadiene-styrene copolymers (Vol. 19, Suppl. 7; 1987)
Actinomycin D [50-76-0] (Vol. 10, Suppl. 7; 1987)
Agaritine [2757-90-6] (Vol. 31, Suppl. 7; 1987)
Aldicarb [116-06-3] (Vol. 53; 1991)
Aldrin [309-00-2] (Vol. 5, Suppl. 7; 1987)
Allyl chloride [107-05-1] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Allyl isothiocyanate [57-06-7] (Vol. 73; 1999)
Allyl isovalerate [2835-39-4] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Amaranth [915-67-3] (Vol. 8, Suppl. 7; 1987)
5-Aminoacenaphthene [4657-93-6] (Vol. 16, Suppl. 7; 1987)
2-Aminoanthraquinone [117-79-3] (Vol. 27, Suppl. 7; 1987)
para-Aminobenzoic acid [150-13-0] (Vol. 16, Suppl. 7; 1987)
1-Amino-2-methylanthraquinone [82-28-0] (Vol. 27, Suppl. 7; 1987)
2-Amino-4-nitrophenol [99-57-0] (Vol. 57; 1993)
2-Amino-5-nitrophenol [121-88-0] (Vol. 57; 1993)
4-Amino-2-nitrophenol [119-34-6] (Vol. 16, Suppl. 7; 1987)
2-Amino-5-nitrothiazole [121-66-4] (Vol. 31, Suppl. 7; 1987)
11-Aminoundecanoic acid [2432-99-7] (Vol. 39, Suppl. 7; 1987)
Amitrole [61-82-5] (Vol. 79; 2001)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Ampicillin [69-53-4] (Vol. 50; 1990)
Anaesthetics, volatile (Vol. 11, Suppl. 7; 1987)
Angelicin [523-50-2] plus ultraviolet A radiation (Vol. 40, Suppl. 7; 1987)
Aniline [62-53-3] (Vol. 27, Suppl. 7; 1987)
para-Anisidine [104-94-9] (Vol. 27, Suppl. 7; 1987)
Anthanthrene [191-26-4] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Anthracene [120-12-7] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Anthranilic acid [118-92-3] (Vol. 16, Suppl. 7; 1987)
Antimony trisulfide [1345-04-6] (Vol. 47; 1989)
Apholate [52-46-0] (Vol. 9, Suppl. 7; 1987)
para-Aramid fibrils [24938-64-5] (Vol. 68; 1997)
Atrazine [1912-24-9] (Vol. 73; 1999)
(NB: Overall evaluation downgraded from 2B to 3 with supporting
evidence from other relevant data)
Aurothioglucose [12192-57-3] (Vol. 13, Suppl. 7; 1987)
2-(1-Aziridinyl)ethanol [1072-52-2] (Vol. 9, Suppl. 7; 1987)
Aziridyl benzoquinone [800-24-8] (Vol. 9, Suppl. 7; 1987)
Azobenzene [103-33-3] (Vol. 8, Suppl. 7; 1987)
11H-Benz[bc]aceanthrylene [202-94-8] (Vol. 92; in preparation)
Benz[l]aceanthrylene [211-91-6] (Vol. 92; in preparation)
Benz[a]acridine [225-11-6] (Vol. 32, Suppl. 7; 1987)
Benz[c]acridine [225-51-4] (Vol. 32, Suppl. 7; 1987)
Benzo[b]chrysene [214-17-5] (Vol. 92; in preparation)
Benzo[g]chrysene [196-78-1] (Vol. 92; in preparation)
Benzo[a]fluoranthene [203-33-8] (Vol. 92; in preparation)
Benzo[ghi]fluoranthene [203-12-3] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[a]fluorene [238-84-6] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[b]fluorene [243-17-4] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[c]fluorene [205-12-9] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[ghi]perylene [191-24-2] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
Benzo[e]pyrene [192-97-2] (Vol. 32, Suppl. 7, Vol. 92; in preparation)
para-Benzoquinone dioxime [105-11-3] (Vol. 29, Suppl. 7, Vol. 71; 1999)
Benzoyl peroxide [94-36-0] (Vol. 36, Suppl. 7, Vol. 71; 1999)
Benzyl acetate [140-11-4] (Vol. 40, Suppl. 7, Vol. 71; 1999)
Bis(1-aziridinyl)morpholinophosphine sulfide [2168-68-5] (Vol.9, Suppl. 7; 1987)
Bis(2-chloroethyl)ether [111-44-4] (Vol. 9, Suppl. 7, Vol. 71; 1999)
1,2-Bis(chloromethoxy)ethane [13483-18-6] (Vol. 15; Suppl. 7, Vol. 71; 1999)
1,4-Bis(chloromethoxymethyl)benzene [56894-91-8] (Vol. 15, Suppl. 7, Vol. 71; 1999)
Bis(2-chloro-1-methylethyl)ether [108-60-1] (Vol. 41, Suppl. 7, Vol. 71; 1999)
Bis(2,3-epoxycyclopentyl)ether [2386-90-5] (Vol. 47, Vol. 71; 1999)
Bisphenol A diglycidyl ether (Aralditeâ) [1675-54-3] (Vol. 47, Vol. 71; 1999)
Bisulfites (Vol. 54; 1992)
Blue VRS [129-17-9] (Vol. 16, Suppl. 7; 1987)
Brilliant Blue FCF, disodium salt [3844-45-9] (Vol. 16, Suppl.7; 1987)
Bromochloroacetonitrile [83463-62-1] (Vol. 52, Vol. 71; 1999)
Bromoethane [74-96-4] (Vol. 52, Vol. 71; 1999)
Bromoform [75-25-2] (Vol. 52, Vol. 71; 1999)
2-Butoxyethanol [111-76-2] (Vol. 88; 2006)
1-tert-Butoxypropan-2-ol
[57018-52-7] (Vol. 88; 2006)
n-Butyl acrylate [141-32-2] (Vol. 39, Suppl. 7,
Vol. 71; 1999)
Butylated hydroxytoluene (BHT) [128-37-0] (Vol. 40, Suppl. 7;1987)
Butyl benzyl phthalate [85-68-7] (Vol. 73; 1999)
![[../../images/icons/group.png]](http://www.occupmedicine.com/uploads/images/../../images/icons/group.png "[../../images/icons/group.png]"){kind=icon}
![[../../images/icons/page_edit.png]](http://www.occupmedicine.com/uploads/images/../../images/icons/page_edit.png "[../../images/icons/page_edit.png]"){kind=icon}
Page last modified on 29-Apr-2007
![[../../images/icons/arrow_up.png]](http://www.occupmedicine.com/uploads/images/../../images/icons/arrow_up.png "[../../images/icons/arrow_up.png]"){kind=icon}
Back to top
Add A Comment